A phase II study assessing REVTx-99 in early stage COVID‑19 patients at risk for hospitalization
Latest Information Update: 01 Sep 2021
At a glance
- Drugs Glycopyranosyl lipid adjuvant (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Revelation Biosciences
- 30 Aug 2021 According to a Revelation Biosciences media release, the company expect to initiate Phase 2 viral challenge study in the first quarter of 2022.
- 05 May 2021 According to a Revelation Biosciences media release, the company expect to initiate this study in the second half of 2021.
- 08 Oct 2020 New trial record